General
Preferred name
ALTRETAMINE
Synonyms
Altretaminum ()
Altretamine (hydrochloride) ()
ENT-50852 hydrochloride ()
RB-1515 hydrochloride ()
WR-95704 hydrochloride ()
ENT50852 ()
ENT-50852 ()
RB-1515 ()
WR-95704 ()
Hexamethylmelamine, NSC13875, ENT50852 ()
N2,N2,N4,N4,N6,N6-hexamethyl-1,3,5-triazine-2,4,6-triamine ()
AltretamineHexalenHemelHexamethylmelamine2,4,6-Tris(dimethylamino)-s-triazines-Triazine, 2,4,6-tris(dimethylamino)-2,4,6-Tris(dimethylamino)-1,3,5-triazineHexastatENT 50852NSC 13875 ()
NSC-13875 ()
Hexalen ()
Hexamethylmelamine ()
Hexastat ()
Altretamina ()
P&D ID
PD001093
CAS
645-05-6
2975-00-0
15468-34-5
Tags
available
drug
Approved by
FDA
First approval
1990
Drug indication
Ovarian cancer
Neoplasm
Drug Status
approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Altretamine is a DNA alkylating agent
(GtoPdb)
DESCRIPTION
Altretamine is an alkylating antineoplastic agent.
PRICE
29
DESCRIPTION
Altretamine (ENT-50852) is an alkylating agent with antineoplastic activity.
DESCRIPTION
Antineoplastic
(LOPAC library)
DESCRIPTION
Altretamine is an anti-neoplastic agent.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Altretamine is an antineoplastic agent with antiproliferative activity. It is indicated for use as a single agent in the palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent-based combination.
(Enamine Bioactive Compounds)
DESCRIPTION
PUBCHEM_BIOASSAY: Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2. (Class of assay: confirmatory)
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
2
Organisms
1
Compound Sets
31
AdooQ Bioactive Compound Library
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine Bioactive Compounds
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NIH Approved Oncology Drugs
NIH Clinical Collections (NCC)
NPC Screening Collection
Other bioactive compounds
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
47
Molecular Weight
210.16
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
0
Rotatable Bonds
3
Ring Count
1
Aromatic Ring Count
1
cLogP
0.07
TPSA
48.39
Fraction CSP3
0.67
Chiral centers
0.0
Largest ring
6.0
QED
0.7
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
DNA alkylator/crosslinker
DNA
Pathway
Cell Cycle/DNA Damage
MOA
DNA alkylator
DNA synthesis inhibitor
Indication
ovarian cancer
Therapeutic Class
Anticancer Agents
Source data
